Research Funding Opportunities
We want to help kidney cancer researchers locate funding opportunities. We’ll update this page with grant opportunities as we learn about them.
Know of one we haven’t listed? Email us at info@kidneycan.org, or tweet at us, and we’ll get it posted!
KidneyCAN is dedicated to accelerating kidney cancer research.
Our advocacy for the DoD Kidney Cancer Research Program resulted in appropriations of $50 million in fiscal year 2023 for kidney cancer research, bring the 2017-2023 total to $235 million. In 2016, this number was $0.
The Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting.
Additionally, KidneyCAN’s “Rock the Cure” events have raised over $1,000,000 toward private research support.
KCRP FY23 FUNDING OPPORTUNITIES RELEASED
DUE JULY-SEPTEMBER
- Academy of Kidney Cancer Scholars – Early-Career Scholar Award
- Clinical Trial Award
- Concept Award
- Idea Development Award (New for FY23: Partnering Principal Investigator Option)
- Nurse-Initiated Research Award
- Postdoctoral and Clinical Fellowship Award
- Translational Research Partnership Award
ARPA-H supports high-impact biomedical research for equitable health solutions. Their model empowers program managers to tackle problems by working with a range of performers and approaches, and emphasizing measurement and evaluation for real-world impact.
The Advanced Research Projects Agency for Health (ARPA-H) seeks proposals for high-impact biomedical and health research to tackle society’s most challenging health problems, including cancer. The agency will fund groundbreaking, innovative research that can rapidly achieve better health outcomes across patient populations, communities, diseases, and health conditions.
Proposals must use novel approaches to enable revolutionary advances in science, technology, or systems. ARPA-H has identified four initial focus areas:
-
- Health Science Futures
- Scalable Solutions
- Proactive Health
- Resilient Systems
ARPA-H may consider submissions outside of these areas if they develop novel capabilities to improve health outcomes or prolong well-being. The agency will fund efforts across the spectrum of technology readiness, from foundational science to introducing new prototypes into the marketplace.
FUNDING OPPORTUNITY ANNOUNCEMENT
ARPA-H FREQUENTLY ASKED QUESTIONS
“ARPA-H will support concepts brought to life directly from Program Managers that have not only identified a key problem in health today, but are also passionate about a vision to bring forward revolutionary solutions to solve the problem, and do so in an equitable way.
“ARPA-H embraces a culture of open innovation and empowers its Program Managers to fearlessly pursue health breakthroughs that cannot readily be accomplished through traditional research or commercial activity. Program Managers at ARPA-H will serve an initial appointment of three years, and no more than six years total, to ensure a constant rotation of new ideas and diverse perspectives.”
Since 1993, the American Association for Cancer research has awarded more than $540 million in funds toward almost 1,000 different grants. In 2021, the AACR awarded over $7 million.
The ACCR supports grantees from the United States and abroad, at every career stage. These grants accelerate cancer research.
We’d love to see more RCC applicants for these prestigious grant opportunities.
KidneyCAN hosted the 5th Annual Kidney Cancer Research Summit on July 13–14, 2023, live in Boston, Massachusetts at the InterContinental Boston and virtually via Zoom webinar.
KCRS is an annual meeting of clinicians, researchers, research advocates, scientists, medical oncologists, industry and others to discuss the future efforts for collaboration in the field of kidney cancer research.
Learn more about KCRS and pre-register for KCRS24 now by visiting the website.
Kidney cancer is the ideal sandbox for these new approaches, and without a doubt the same approach can, should and will be suitable for other cancers.
Dr. Hans Hammers, UTSW
RESEARCH UPDATES
Dr. Yousef Zakharia: “I Believe in Teamwork”
For this Community Spotlight feature, we spoke to Dr. Yousef Zakharia, a medical oncologist at the Holden Comprehensive Cancer Center and associate professor at the University of Iowa. Dr. Zakharia shares important information about finding the best care at...
Dr. Moshe Ornstein: A Journey of Advocacy, Research, and Community in Kidney Cancer
This month, we asked Dr. Moshe Ornstein to share his insights in kidney cancer research and advocacy. He is a dedicated kidney cancer physician and researcher at the Cleveland Clinic. Dr. Ornstein completed his fellowship in Hematology & Oncology at the Cleveland...
From the Heart to the Hill: Advocating for Kidney Cancer Research Funding
Spring Advocacy : By the Numbers KidneyCAN is thrilled to announce the success of our Spring Advocacy Days event, which took place on March 13th in person in Washington, D.C., and on March 14th virtually. We are grateful for the 186 confirmed meetings with...
Join Our Grassroots Army
;
@kidneycan Thank you for being there and doing this important advocacy work. Looking good! 🧡
Today, KidneyCAN advocates are on #CapitolHill requesting $60M for the #KidneyCancer Research Program (KCRP) in FY24 and $50.9 billion to the #NIH, including $9.988 billion for the #NCI. This funding is critical for advancing research and #acceleratingcures!
#AdvocacyInAction
🚨 REMINDER: Last chance to 🗳️ in @ASCO Elections!
⏲️ DEADLINE: Monday, Dec. 4th at 3:00PM EST
Proud to support:
🌟The incomparable GU Oncology legend & mentor, @DrChoueiri!
🌟Our indefatigable #ASCOAdvocacy leader & past @ASCO Gov't Relations Committee Chair, @DrJasonWestin!
@montypal @LauraBukavinaMD @CaseUrology @scientistatlrge @FoxChaseCancer @NimaSharifiMD @dsui_miami_uro @lissmike @UTSA @EurUrolOncol @biorxivpreprint @spsutkaMD @DrChoueiri @NazliDizman @ZeynepZengin @ERPlimackMD @neerajaiims @shilpaonc @UroOnc We are very excited about our new trial @cityofhope in metastatic #RCC using a powerful combination of Nivo/Ipi with camu camu, a Brazilian berry, which has shown some remarkable efficacy in refractory melanoma
@kidneycan @KidneyCancer @EAUYAU_RenalCa @MOASC_Office @IKCCorg
Great advice from @Robert_Uzzo accepting the Joseph A. Smith Mentorship Award at #SUO23
✅Take Inventory
📉Embrace Failure
⏩Move Forward
🙏Be Grateful
Congratulations! So very well deserved.
#FoxChaseProud @FoxChaseCancer @FCUroOnc
It took @KyleBlumMD 6 years of work to develop this sarcomatoid RCC consortium. Willing to bet that breakthroughs regarding this aggressive RCC phenotype are going to culminate from his hard work!
Click to learn more about a great project to understand host-tumor immune response by @jjroetman and @philiplabvandy - and kudos for a gorgeous piece of science art! 🩷🩷🩷
Did anyone catch @Jeopardy from this week? One of @ASCO's founders was featured as a clue 🥰 #chemotherapy
Congratulations, @Robert_Uzzo @FoxChaseCancer 🤩
Kicking off the morning #2 at SUO23 with a #KidneyCancer session featuring an outstanding presentation on small renal masses by @drphil_urology - a great way to start the day w/☕️
Good morning! ☀️ Kicking off the final day of #SUO23 with our 💫 lineup at the YUO program - the rising stars of @UroOnc take the big stage to share their impressive work! (1/x)
As #SUO23 comes to an end, we’d like to thank @Scarps_kristen & @zklaassen_md for their leadership and service to the YUO! 👏👏
Welcoming the new YUO chairs @samsimsal & @gershmanMD, as well as new committee members @BogdanaSchmidt @RichMatulewicz @Uro_POM @RuchikaTalwarMD
📺 WATCH: Dr. Srinivasan with our @NCICCR_UroOnc branch spoke with @kidneycan about the resources we provide for rare and hereditary #KidneyCancers here at @theNCI 👇
Voting for the @ASCO Election remains open. Honored to be running as a candidate for a Board of Directors seat!
To vote: https://old-prod.asco.org/about-asco/asco-overview/asco-election
Thank you for voting!
@OncoAlert @OncBrothers @DanaFarber
